A review of onabotulinumtoxinA (Botox).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M. Sykes, Heidi A. Waldorf

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
Pages (from-to)9S-12S
JournalUnknown Journal
Issue number1 Suppl
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'A review of onabotulinumtoxinA (Botox).'. Together they form a unique fingerprint.

Cite this